Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2007 October;98(5) > Minerva Medica 2007 October;98(5):575-89



A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2007 October;98(5):575-89


Meningococcal disease: a review on available vaccines and vaccines in development

Bröker M. 1, Fantoni S. 2

1 Novartis Vaccines Marburg, Germany
2 Novartis Vaccines Siena, Italy

Meningococcal disease continue to have a major public health impact in many countries. Five major groups of Neisseria meningitidis (A, B, C, Y and W135) are responsible for most meningococcal diseases. Plain polysaccharides vaccines for Neisseria meningitidis groups A, C, Y and W-135 have been in use for approximately 20 years, both to prevent invasive disease in high-risk population and to control disease outbreaks. However, these conventional meningococcal vaccines induce a relatively short-lasting T-cell independent immune response, are not effective in children under two years of age and can induce hyporesponsiveness. New meningococcal group C conjugate vaccines have since been developed, which offer solid advantages over the currently licensed plain polysaccharide vaccines. Tetravalent serogroup A, C, Y and W135 meningococcal vaccines are under development and one has already been licensed. There is still no universal vaccine available against the serogroup B, which is a major cause of invasive disease. This report summarises the different approaches to the development of vaccines against the pathogenic meningococci.

language: English


top of page